stockrow
Friday 6 November 2026
Export IMNM’s income statement to Excel — free account
Immunome, Inc.
IMNM Healthcare Biotechnology
Immunome, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.9 million, down 23.2% from fiscal 2024.
- Revenue
- +69.8%
- EPS
- −30.0%
- Free cash flow
- −27.0%
Quarter to June 2026, against a year earlier
18.78
0.87
+4.86%
Follow IMNM
Alert me
Immunome, Inc. (IMNM) Net income
Immunome, Inc.'s net income for fiscal 2025 was −$212.4M, compared with −$293.0M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$254.3M. Over the past ten years it has ranged from −$293.0M (fiscal 2024) to $0.00 (fiscal 2017); the current reading is higher than 22% of that period. Immunome, Inc. ranks 546th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$212.4M | — |
| FY2024 | −$293.0M | — |
| FY2023 | −$106.8M | — |
| FY2022 | −$36.9M | — |
| FY2021 | −$24.7M | — |
| FY2020 | −$17.8M | — |
| FY2019 | −$10.4M | — |
| FY2018 | −$7.8M | — |
| FY2017 | $0.00 | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | −$73.1M | — |
| Mar 2026 | −$53.8M | — |
| Dec 2025 | −$69.9M | — |
| Sep 2025 | −$57.5M | — |
| 25 more quarters | Free account |
Against its own ten years
Low −$293.0M
High $0.00
Ten-year median
−$24.7M
Current reading's percentile
22
Net income against peers
| Company | Net income |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | $314.3M |
| ADMA ADMA Biologics Inc compare | $182.4M |
| VCEL Vericel Corporation compare | $33.3M |
| PVLA Palvella Therapeutics, Inc. compare | −$61.7M |
| IMNM Immunome, Inc. | −$254.3M |
| CLDX Celldex Therapeutics, Inc. compare | −$300.5M |
| VERA Vera Therapeutics, Inc. compare | −$401.9M |
| BHVN Biohaven Ltd. compare | −$542.7M |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | −$652.4M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on IMNM
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Altman Z-score
- The full statement